RC
AVIR icon

Rangeley Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Rangeley Capital’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Sell
46,500
-33,500
-42% -$154K 0.24% 84
2025
Q4 		$286K Hold
80,000
– – 0.24% 73
2025
Q3 		$232K Buy
80,000
+27,000
+51% +$92.2K 0.2% 84
2025
Q2 		$191K Buy
+53,000
New +$158K 0.23% 50

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Rangeley Capital's AVIR Position: Q1 2026 in Review

Rangeley Capital reduced its Atea Pharmaceuticals (AVIR) stake by 42% in Q1 2026, selling an estimated $154K and leaving 46,500 shares worth $250K. The position accounts for 0.24% of the portfolio, ranked #84.

Rangeley Capital first reported a position in AVIR in Q2 2025 and has held it in 4 quarters since. The position peaked at $286K in Q4 2025. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Rangeley Capital held 46,500 shares of Atea Pharmaceuticals worth $250K as of Q1 2026.
  • Rangeley Capital sold 33,500 Atea Pharmaceuticals shares in Q1 2026, an estimated $154K.
  • Atea Pharmaceuticals made up 0.24% of Rangeley Capital's portfolio in Q1 2026, its #84 holding.
  • Rangeley Capital first reported a position in Atea Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Rangeley Capital's Atea Pharmaceuticals position peaked at $286K in Q4 2025.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.